Another note from Citi said that while revenue for Dr. Reddy’s in the current financial year could reach between $80 million to $100 million in a three-player market, with a mandatory generic discount of 65%, a significant upside towards $150 million to $180 appears “improbable” as that will need absence of competition and no price cuts from innovators.
